Press releases & news
2cureX publishes interim report for the third quarter of 2023Read more
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)Read more
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMAN I 2CUREX AB (PUBL)Read more
IndiTreat® Image Uploader gets IVD CE-MarkRead more
Share InformationSee our latest share information
Calendar & upcoming events
2cureX Webcast – Join us at 20:00 CET on October 26 for the latest news from the third quarter of 2023 and a Q&A with the 2cureX Management.Watch webcast
Commentary on Q2 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q2 2023 report.Watch webcast
2cureX Webcast – Get the latest news from the second quarter of 2023 and Q&A with the Management of 2cureX.Watch webcast
STAY UPDATED WITH OUR NEWS AND PRESS RELEASES
Get notified by mail when news or press releases are published on our website.
In this latest blog, Fernando Andreu talks about the exciting expansion of the IndiTreat® product family to include a functional drug sensitivity test for pancreatic cancer in the near future.
Subscribe to our newsletter above.More
Information for Oncologists and Pathologists
Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.
Information for Patients
You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.More